Lantern Pharma Inc.
NASDAQ:LTRNBiotechnology
-$0.19 today
- Market cap
- $50.14M
- Beta
- 2.32
- P/E (TTM)
- -2.7
- EPS (TTM)
- -$1.41
Volume 0.10M
Average 0.68M
LTRN Total Current Liabilities
All obligations due within one year.
Lantern Pharma Inc.NASDAQ: LTRN
Total Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total current liabilities falls 11.9% from a year ago
Total current liabilities stood at $3.78M at the end of Q1 FY2026, down 11.9% from a year earlier and down 99.9% from the prior quarter. Over 3 fiscal years it compounded at +1071.7% a year.
Context
- Total current liabilities amounted to 52.3% of total assets at the end of Q1 FY2026, up 32.0 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -11.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 4.5B USD
- Year-over-year change
- +103834.5%
- 4-year CAGR
- +563.3%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.5B | +103834.5% |
| FY2024 | 2024-12-31 | 4.33M | +61.7% |
| FY2023 | 2023-12-31 | 2.68M | -4.3% |
| FY2022 | 2022-12-31 | 2.8M | +20.3% |
| FY2021 | 2021-12-31 | 2.33M | — |
Total Current Liabilities vs competitors
How LTRN compares with its peers on the latest reported figures
- LTRN's Mar 2026 total current liabilities of $3.78M is the 4th highest of the 5 companies compared; the peer median is $7.79M.
- Its year-over-year change of -11.9% is the lowest of 5, against a peer median of +18.2%.
- Total current liabilities amounts to 52.3% of total assets for LTRN, versus a peer median of 20.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $12.79M | +410.7% | -22.1% | 78.7% | |
| Jun 2026 | $9.26M | +11.4% | -9.2% | 23.1% | |
| Mar 2026 | $6.32M | +25.0% | +21.3% | 17.9% | |
| Mar 2026 | $3.78M | -11.9% | +1071.7% | 52.3% | |
| Mar 2026 | $1.92M | +10.6% | +21.2% | 13.7% | |
| Peer median (excluding LTRN) | $7.79M | +18.2% | +6.0% | 20.5% | |
Competitors are the stored peer set for LTRN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 51.52M | 37.2M | 21.94M | 7.51M | 4.42B |
| Short-term Investments | 19.2M | 17.99M | 19.36M | 16.5M | 5.7B |
| Net Receivables | 181K | 0 | 860K | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 378.95K | 541.18K | 745.65K | 1.23M | 683.95M |
| Total Current Assets | 72.72M | 58.72M | 43.34M | 25.25M | 10.8B |
| Property, Plant & Equipment (Net) | 216.19K | 95.7K | 280.42K | 287.43K | 107.47M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 1M | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 17.89K | 17.89K | 25.87K | 36.74K | 125.17M |
| Total Non-current Assets | 1.23M | 113.58K | 306.29K | 324.16K | 232.64M |
| Total Assets | 73.95M | 58.84M | 43.65M | 25.57M | 11.04B |
| Account Payables | 2.17M | 0 | 942.21K | 0 | 0 |
| Short-term Debt | 152.06K | 0 | 0 | 0 | 78.54M |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 2.75M | 1.56M | 4.14M | 4.42B |
| Total Current Liabilities | 2.33M | 2.8M | 2.68M | 4.33M | 4.5B |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 52.89K | 0 | 61.5K | 52.84K | 0 |
| Total Liabilities | 2.38M | 2.8M | 2.74M | 4.38M | 4.5B |
| Common Stock | 1.11K | 1.09K | 1.07K | 1.08K | 1.13M |
| Retained Earnings | (25.02M) | (39.28M) | (55.24M) | (76.03M) | (93.15B) |
| Accumulated OCI | (92.69K) | (371.39K) | (107.46K) | 153.99K | 25.43M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 99.65B |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 71.57M | 56.04M | 40.91M | 21.19M | 6.53B |
| Total Debt | 204.95K | 52.89K | 234.47K | 243.66K | 78.54M |
| Net Debt | (51.32M) | (37.15M) | (21.7M) | (7.27M) | (4.34B) |
Lantern Pharma Inc.
NASDAQ:LTRN
Intrinsic Alpha fair value
Locked
Current Price
$3.93
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.